Before analyzing biotech stocks, it’s important to analyze the biotech sector itself.
In this video, we review the SPDR S&P Biotech ETF (XBI) across the weekly, monthly, and quarterly timeframes to determine whether the sector remains technically healthy.
Topics covered:
Weekly technical outlook
Monthly breakout analysis
Quarterly momentum review
Moving averages
MACD analysis
Long-term biotech trend
What XBI may mean for biotech investors
Our Take
XBI remains technically constructive across all major timeframes.
Weekly trend remains higher.
Monthly breakout remains intact.
Quarterly momentum remains positive.
While no chart can predict the future, understanding the health of the sector provides valuable context before evaluating individual biotech companies.
Before analyzing biotech stocks, analyze biotech itself.
Disclosure: I have no position in XBI. Quiet Bull is for informational and educational purposes only and should not be considered personalized investment advice or a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal.
